市場調查報告書
商品編碼
1190483
肌酐檢測試劑盒市場——增長、趨勢、COVID-19 的影響和預測 (2023-2028)Creatinine Assay Kits Market - Growth, Trends, and Forecasts (2023 - 2028) |
※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。
在預測期內,肌酐檢測試劑盒市場的複合年增長率預計為 5.3%。
血清肌酐是最廣泛使用的腎功能測試之一。 它用於推導出作為腎功能指標的估計腎小球濾過率 (eGFR)。 它還被用作確定慢性腎病的最佳指標。 血液中的肌酐濃度與腎小球濾過率 (GFR) 呈負相關,是腎功能的理想指標。 然而不幸的是,測量 GFR 非常耗時,因此 GFR 通常是根據考慮了血清肌酐 (sCr) 等內源性濾過標記物的公式來估算的。
慢性腎病患病率上升、研發活動增加、主要參與者採取重大戰略舉措以及血清肌酐測試的推出和進步正在推動市場增長。 根據 2022 年 2 月發布的 PubMed 數據,亞洲中低收入國家的慢性腎病患病率明顯更高,約為 11.2%。 出於這個原因,對肌酐測試的需求正在增加,推動了市場。
此外,全球範圍內該領域不同機構對血清肌酐的研究和研究合作越來越多。 例如,2021 年 9 月,美國國家腎臟基金會 (NKF) 和美國腎臟病學會 (ASN) 工作組宣布採用新的 eGFR 2021 CKD EPI(慢性腎臟病流行病學夥伴關係)肌酐公式來估計腎功能,不分種族變量。我們制定了法規 工作組還建議擴大使用胱抑素 C 聯合血清(血液)肌酐作為腎功能的確認評估。 這些努力將增加對血清肌酐生物標誌物測試的需求。
由於該地區腎臟疾病和其他影響腎功能的慢性疾病的發病率不斷增加,以及腎臟疾病生物醫學研究的技術進步,北美在全球肌酐檢測試劑盒市場中佔有很大份額。
根據 2021 年 3 月 CDC 數據,估計約有 3700 萬人(占美國成年人的 15%)患有慢性腎病 (CKD)。 據估計,慢性腎臟病 (CKD) 在女性 (16%) 中比在男性 (13%) 中更常見。 此外,有利的保險報銷政策和完善的醫療基礎設施正在極大地推動整個地區的市場增長。
此外,新產品在該國的推出以及主要市場參與者越來越多地採用擴張戰略也有望提振市場。 2022 年 7 月,莫菲特癌症中心的研究人員確定了腎細胞癌的生物標誌物。 基於他們的生物標誌物表達,我們開發了一種工具來指示哪些患者預後不良的風險很高。 預計這些研發活動將在預測期內促進腎臟疾病生物標誌物測試的發展。 同樣,2021 年 4 月,Renalytix AI PLC 與喬斯林糖尿病中心簽訂了獨家選擇權協議,為腎臟疾病的某些其他新型生物標誌物申請專利,以便在 KidneyIntelXin 體外預後平台上進行開發和部署。 這表明開發腎臟疾病生物標誌物測試的研發活動有所增加,這正在推動市場增長。
肌酐檢測試劑盒市場是一個高度分散且競爭激烈的市場,由幾家大型企業組成。 從市場份額的角度來看,目前大多數玩家佔據了市場主導地位。 目前主導市場的公司包括 Abbott Laboratories、Thermo Fisher Scientific、Merck KGaA、Quidel Corporation、Cell Biolabs Inc、Genway Biotech、Randox Laboratories Ltd、ACON Laboratories、Nova Biomedical 和 Sysmex India Pvt。
The creatinine assay kits market is expected to register a CAGR of 5.3% during the forecast period.
Serum creatinine is one of the most widely used laboratory tests for kidney function. It is used to derive the estimated glomerular filtration rate (eGFR) as an indicator of kidney function. It is also used as an ideal indicator for the determination of chronic kidney diseases. The creatinine concentration in blood is inversely proportional to the glomerular filtration rate (GFR), which is an ideal marker of kidney function. Unfortunately, measuring GFR is time-consuming, and therefore GFR is usually estimated from equations that consider endogenous filtration markers like serum creatinine (sCr).
The growing incidence of chronic kidney disease, rising R&D activities, adoption of key strategic initiatives by major players, and the growing launches and advancement in serum creatinine tests are boosting the market growth. As per the PubMed data published in February 2022, the prevalence of chronic kidney disease in Asia in low- and middle-income countries was around 11.2%, which was significantly high. This increases the demand for creatinine tests, thereby driving the market.
Additionally, the research on serum creatinine and the collaborations by various organizations in this area are increasing worldwide. For instance, in September 2021, the National Kidney Foundation (NKF) and the American Society of Nephrology (ASN) Task Force rolled out regulations for the adoption of the new eGFR 2021 CKD EPI (chronic kidney disease epidemiology collaboration) creatinine equation that estimated kidney function without a race variable. The task force also recommended increased use of cystatin C combined with serum (blood) creatinine as a confirmatory assessment of kidney function. Such initiatives are likely to boost the demand for serum creatinine biomarker tests.
North America is expected to hold a significant share in the global creatinine assay kits market due to the increasing incidence of renal disorders and other chronic disorders impacting renal function and technological advancements in biomedical research about kidney disorders in this region.
According to the CDC data from March 2021, approximately 37 million people, or 15% of US adults, are estimated to have chronic kidney disease (CKD). Chronic kidney disease (CKD) is estimated to be more common in women (16%) than in men (13%). Furthermore, favorable reimbursement policies and well-established healthcare infrastructure are fueling the growth of the overall regional market to a large extent.
Furthermore, the launch of new products in the country and the rising adoption of expansion strategies by key market players are expected to boost the market. In July 2022, Moffitt Cancer Center researchers identified biomarkers for renal cell carcinoma. Based on its biomarker expression, it developed a tool to indicate which patients are at high risk of poor outcomes. Such R&D activities are expected to boost the development of biomarker tests for kidney diseases during the forecast period. Similarly, in April 2021, Renalytix AI PLC entered an exclusive option agreement with Joslin Diabetes Center for patent filings on specific additional novel biomarkers in kidney disease for development and deployment in the KidneyIntelXin Vitro prognostic platform. This indicates the rise in R&D activities for developing biomarkers tests for kidney diseases, thereby driving the market growth.
The creatinine assay kits market is highly fragmented and competitive and consists of several major players. In terms of market share, the majority of the players are currently dominating the market. Some of the companies which are currently dominating the market are Abbott Laboratories, Thermo Fisher Scientific, Merck KGaA, Quidel Corporation, Cell Biolabs Inc., Genway Biotech, Randox Laboratories Ltd, ACON Laboratories, Nova Biomedical, and Sysmex India Pvt. Ltd.